Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 11/20 | 0.51 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.44 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.44 |
| ▸ | JAK3 | P52333 | 1/20 | 0.44 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 2/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GMPS | P49915 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24105214 | 0.90 | AURKA (0.53) | TTKMAPKAPK5MEN1MAPTKMT2A | |
| SCHEMBL24105022 | 0.88 | TTK (0.52) | TTKMAPKAPK5MEN1MAPTKMT2A | |
| SCHEMBL24105215 | 0.82 | SRC (0.49) | TTKMAPKAPK5MAPTGAAAURKA | |
| SCHEMBL30371440 | 0.82 | SRC (0.49) | TTKMAPKAPK5MAPTGAAAURKA | |
| SCHEMBL22122900 | 0.82 | TTK (0.54) | TTKJAK3MAPKAPK5AURKASRC | |
| SCHEMBL3466981 | 0.81 | SRC (0.56) | TTKMAPKAPK5MEN1MAPTKMT2A | |
| SCHEMBL22122895 | 0.81 | TTK (0.52) | TTKMAPKAPK5AURKASRC | |
| SCHEMBL25174057 | 0.80 | TTK (0.52) | TTKMAPKAPK5MEN1MAPTKMT2A | |
| SCHEMBL24105025 | 0.80 | PTK6 (0.49) | TTKMAPKAPK5AURKA | |
| SCHEMBL30167789 | 0.80 | PTK6 (0.49) | TTKMAPKAPK5AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115667264-A | Novel imidazo-pyrazine derivatives | 豪夫迈·罗氏有限公司 | 2023-01-31 | — | — | CN | claimed |
| US-20230141403-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230141403-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-05-11 | — | — | US | disclosed |
| CN-115667264-A | Novel imidazo-pyrazine derivatives | 豪夫迈·罗氏有限公司 | 2023-01-31 | — | — | CN | disclosed |
| WO-2021249893-A1 | NOVEL IMIDAZO-PYRAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2021-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230141403-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | XDH, MYD88, IKZF3 | TTK 4157/4885MALT1 527/4885ZAP70 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.